Supernus Pharmaceuticals, Inc.

Supernus is a late-stage neuroscience company focused on developing specialty products using its patented and proven technologies and product development capabilities. In 2012 the company received market approval for Oxtellar, and tentative approval for Trokendi. Two ADHD products are in Phase II of development.